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Choline kinase is the first enzyme in the Kennedy pathway (CDP-choline pathway) for the biosynthesis of the
most essential phospholipid, phosphatidylcholine, in Plasmodium falciparum. In addition, choline kinase also plays
a pivotal role in trapping essential polar head group choline inside the malaria parasite. Recently, Plasmodium
falciparum choline kinase (PfCK) has been cloned, overexpressed, and purified. However, the function of this
enzyme in parasite growth and survival has not been evaluated owing to the lack of a suitable inhibitor. Purified
recombinant PfCK enabled us to identify an inhibitor of PfCK, hexadecyltrimethylammonium bromide (HDTAB),
which has a very close structural resemblance to hexadecylphosphocholine (miltefosin), the well-known antiprolif-
erative and antileishmanial drug. HDTAB inhibited PfCK in a dose-dependent manner and offered very potent
antimalarial activity in vitro against Plasmodium falciparum. Moreover, HDTAB exhibited profound antima-
larial activity in vivo against the rodent malaria parasite Plasmodium yoelii (N-67 strain). Interestingly,
parasites at the trophozoite and schizont stages were found to be particularly sensitive to HDTAB. The
stage-specific antimalarial effect of HDTAB correlated well with the expression pattern of PfCK in P. falcip-
arum, which was observed by reverse transcription-PCR and immunofluorescence microscopy. Furthermore,
the antimalarial activity of HDTAB paralleled the decrease in phosphatidylcholine content, which was found
to correlate with the decreased phosphocholine generation. These results suggest that inhibition of choline
kinase by HDTAB leads to decreased phosphocholine, which in turn causes a decrease in phosphatidylcholine
biosynthesis, resulting in death of the parasite.
Phosphatidylcholine (PC) is the most abundant phospho-
lipid in Plasmodium falciparum and is synthesized mainly by (i)
the Kennedy or CDP-choline pathway (40) and (ii) the serine
decarboxylation-phosphoethanolamine methylation pathway,
which eventually shunts to the Kennedy pathway (31). So far,
the Bremer-Greenberg pathway (phosphatidylethanolamine
methylation pathway) for the synthesis of PC has not been
characterized in P. falciparum probably due to the lack of
phosphatidylethanolamine methyltransferase, the key enzyme
in the Bremer-Greenberg pathway in the P. falciparum genome
(www.plasmodb.org). The relative contributions of the first two
pathways for the synthesis of PC have not been addressed;
however, the Kennedy pathway has been suggested to be the
main pathway (31, 40). Choline kinase (ATP:choline phospho-
transferase [EC 2.7.1.32]) is the first enzyme in the Kennedy
pathway (CDP-choline pathway) (see Fig. 1), and inhibition of
this pathway prevents parasite growth (1, 3, 36). Moreover, PC
biosynthesis has been suggested as a realistic target for devel-
opment of new pharmacophores even against pharmacoresis-
tant strains (1, 43). Choline kinase (CK) catalyzes the initial
step in the CDP-choline pathway and can be regulatory for PC
biosynthesis in various biological systems (42, 45), but so far, a
regulatory role for CK in malaria parasites has not been re-
ported, although a positive correlation between the intracellu-
lar phosphocholine pool and PC content had been found under
certain quaternary ammonium compound treatment (4), indi-
cating CK may have the potential to regulate PC biosynthesis
in the malaria parasite also. Recently, we have cloned, over-
expressed, and characterized Plasmodium falciparum choline
kinase (PfCK) (16). The availability of catalytically active re-
combinant PfCK opened an opportunity to identify potent
PfCK inhibitors with a view to explore the function of PfCK.
Here, evidence is presented to establish that hexadecyltrimeth-
ylammonium bromide (HDTAB) inhibits purified PfCK as
well as CK of P. falciparum in culture. The structure of
HDTAB closely resembles the structure of hexadecylphospho-
choline (miltefosin) (Fig. 1), the well-known drug used in che-
motherapy for cancer (10) and leishmaniasis (11, 30). HDTAB
exhibits potent antimalarial activity in vitro and in vivo. Fur-
thermore, evidence has been presented to show that inhibition
of CK in P. falciparum by HDTAB perturbs the Kennedy
pathway which results in parasite death.
MATERIALS AND METHODS
Materials. RPMI 1640 medium, gentamicin, hypoxanthine, N-[2-(p-bromocin-
namylamino)ethyl]-5-isoquinolinesulfonamide (H-89), hemicholinium-3 (HC-3),
HDTAB, trichloroacetic acid, ATP, D-sorbitol, Dowex-50W (H-form), and
anti-rabbit immunoglobulin G (IgG) coupled to horseradish peroxidase were
procured from Sigma (St. Louis, MO). [3H]hypoxanthine, [methyl-14C]choline
chloride, RNase-free DNase, Ready.To.Go reverse transcription-PCR (RT-
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PCR) beads, and Cy2-tagged anti-rabbit IgG antibodies were purchased from
Amersham Biosciences, NJ. RNeasy protect kit was purchased from QIAGEN,
Germany. AlbuMax II and PTC-200 were procured from Gibco and MJ Re-
search, respectively. Diamidino phenylindole (DAPI) and MitoTracker Red
CMXRos were from MBI Fermentas, Hanover, MD, and Molecular Probes, OR,
respectively. The instruments used for cell harvesting and radioactivity measure-
ments were the Harvester 96 MACH III M (Tomtec, CT) and LS6500 multi-
purpose scintillation counter (Beckman Coulter Counter), respectively. Agarose
was from Genei, Banglore, India. Dimethyl sulfoxide (DMSO) was from Thomas
Baker, India. All other chemicals were of analytical grade.
Parasite culture. P. falciparum (clone NF-54) was grown in human B eryth-
rocytes at a hematocrit level of 5% in complete RPMI 1640 medium (CRPMI)
(RPMI 1640 medium supplemented with 25 mM HEPES, 50 g ml1 gentami-
cin, 370 M hypoxanthine, and 0.5% [wt/vol] AlbuMax II) in tissue culture flasks
(25 cm2 and 75 cm2) with loose screw caps by the method of Trager and Jensen
(39). Used medium was changed with fresh medium once in 24 h, and the culture
was routinely monitored through Giemsa staining of thin smears.
Isolation of parasites from infected erythrocytes. Parasites were isolated as
described previously (41). Briefly, erythrocytes with 10% parasitemia were
centrifuged at 800  g for 5 min, washed, and resuspended in cold phosphate-
buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 5.3 mM Na2HPO4, and 1.8
mM KH2PO4). An equal volume of 0.5% saponin in PBS was added to the
erythrocyte suspension (final concentration, 0.25%) and kept on ice for 15 min.
It was centrifuged at 1,300  g for 5 min to obtain a parasite pellet, and then
pellet was washed with PBS thrice. Isolated parasites were either used immedi-
ately or kept at 80°C for later use.
Extraction of RNA, PCR, cloning, overexpression, and purification. Freshly
isolated parasites were immediately suspended in RNAlater solution (QIAGEN),
and RNA was extracted from the parasites using QIAGEN RNeasy protect kit
according to the manufacturer’s instructions. Nucleic acid bound to a RNeasy
column was incubated with 5 Kunitz units of RNase-free DNase in 50 mM Tris-HCl
(pH-7.5) and 10 mM MgCl2 for 20 min at 37°C to remove DNA contamination in
RNA preparations. The gene for putative choline kinase (PfCK) from total RNA
was reverse transcribed and PCR amplified with forward primer 5-GCGGGATC
CGGATGGAAAGCAAAATCTGTGACCCC-3 (BamHI restriction site is under-
lined) and reverse primer 5CCGGAATTCATGATGATGATGATGATGATCG
TCATAATCCTTGATAATATTTTTGG-3 (EcoRI restriction site is underlined
and contains codons for the six-His tag downstream of the EcoRI site). The RT-
PCR-amplified PfCK gene was cloned in pRSET-C, an Escherichia coli expression
vector. The host strain was optimized, and overexpressed PfCK protein was purified
to homogeneity using Ni- nitrilotriacetic acid agarose affinity and gel filtration chro-
matography as described previously (16).
Inhibition of PfCK. Choline kinase activity was measured by the method
described earlier (17) with the following modifications. The activity of PfCK was
evaluated in 96-well plates by incubating PfCK (5 g) in 100 mM Tris-Cl (pH
8.8), 5 mM ATP, 6 mM MgCl2, and 250 M [methyl-14C]choline chloride (spe-
cific activity, 5.6 mCi/mmol) in the absence or presence of different concentra-
tions of H-89, HC-3, and HDTAB at 37°C for 45 min in a total volume of 100 l.
H-89 and HC-3 are known choline kinase inhibitors (8, 44), and HDTAB has
quaternary ammonium groups, which can function as a structural analogue of
choline and may bind to PfCK. For a few experiments with H-89, PfCK activity
was also evaluated at 100 M ATP and 120 M MgCl2, keeping remaining
conditions as such. Similarly, PfCK activity was also evaluated at 100 M choline
in the cases of HC-3 and HDTAB without modifying other variables. Since
compounds were dissolved in DMSO, PfCK activity was also evaluated in the
presence of DMSO and considered 100% PfCK activity. Reactions were termi-
nated by the addition of a 50% slurry of Dowex-50W [H] resin prepared in
absolute alcohol. Following vigorous mixing, resin was allowed to settle under
gravity. Equal volumes of supernatants containing 14C-labeled phosphocholine
formed by PfCK were mixed with 10 ml of scintillation fluid and counted in a
liquid scintillation -counter (Beckman).
Antimalarial activity of HDTAB. The antimalarial activity of HDTAB was
determined in vitro by the [3H]hypoxanthine uptake assay described earlier (20).
Two hundred microliters of P. falciparum asynchronous culture at 1% hematocrit
and 0.5 to 0.7% parasitemia was exposed to various concentrations of HDTAB
in the wells of a 96-well plate for one full parasite cycle (48 h). HDTAB
concentrations were prepared in DMSO and diluted in RPMI 1640 medium.
DMSO-treated parasites were used as a control. After completion of incubation,
cells were washed thrice with CRPMI medium, and [3H]hypoxanthine (0.7 Ci/
well) was added followed by a further incubation for 48 h under optimum growth
conditions. Parasite viability was evaluated by the ability of the parasite to
incorporate [3H]hypoxanthine in its nucleic acid. On completion of incubation,
the cells were harvested on Whatman GF/C glass filters using a cell harvester.
Subsequently, cells were lysed by triple distilled water, and unincorporated ra-
dioactivity on glass filters was removed by three successive washes with triple
distilled water. Radioactivity was retained on filters and represented the incor-
porated [3H]hypoxanthine in parasite nucleic acid. After complete drying of
filters at 30°C, scintillation fluid was added and kept for 24 h before counting in
a liquid scintillation -counter (Beckman).
Antimalarial effect of HDTAB on different stages of Plasmodium falciparum.
The stage-specific activity of HDTAB was evaluated by using the method de-
scribed previously (3). The P. falciparum culture was synchronized as described
earlier (27) using 5% D-sorbitol. The parasitemia in the synchronized culture was
determined from Giemsa-stained thin smears and diluted to desired parasitemia
of 0.5% (ring stage) with uninfected human B red blood cells (RBCs) to a final
hematocrit level of 1%. The diluted culture was kept under optimum growth
conditions, and aliquots were removed at time intervals coinciding with the ring,
trophozoite, and schizont stages. At the appropriate times, rings (0 h), tropho-
zoites (24 h), and schizonts (36 h) were incubated with various concentrations of
HDTAB in 200 l CRPMI for 8 h followed by three successive washings with
CRPMI without hypoxanthine to remove the compound completely. Subse-
quently, parasites were further incubated in CRPMI without hypoxanthine until
[3H]hypoxanthine (0.7 Ci/well) was added at 24 h, 48 h, and 60 h for rings,
trophozoites, and schizonts, respectively. Cultures were finally harvested at 72 h
from Whatman GF/C glass filters with a 96-well cell harvester, and samples were
processed as described above. The DMSO control for each stage was run in
parallel and had received the same treatment as the corresponding stage had.
Stage-specific expression of PfCK. Different erythrocytic stages of parasites
were obtained after preparing ring-synchronized cultures of P. falciparum. Syn-
chronization was done as described earlier (27). Briefly, ring-stage-rich parasite
culture (60 ml, 5% hematocrit) of approximately 10% parasitemia was pelleted
at 800  g, and the pellet (3 ml) was resuspended in 60 ml of 5% D-sorbitol and
incubated for 10 min at 30°C with occasional shaking. Intact cells were separated
from lysed ones by centrifugation at 800  g for 5 min. Cells were aseptically
washed thrice in CRPMI medium and finally diluted to the desired parasitemia
with fresh uninfected human B RBCs, keeping the final hematocrit level 5%.
FIG. 1. Kennedy pathway for phosphatidylcholine biosynthesis and the structures of choline, decyltrimethylammonium bromide, HDTAB, and
hexadecylphosphocholine (miltefosin). The arrow indicates the direction of the pathway. Abbreviations, CK, choline kinase; CCT, choline
phosphate cytidylyltransferase; CPT, choline phosphotransferase; DAG, diacylglycerol; PC, phosphatidylcholine. The probable target enzymes of
the HDTAB and miltefosin are indicated by  bars.
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Synchronization of the culture was confirmed by microscopic examination of
Giemsa-stained thin smears. Parasites harvested from synchronized cultures at
0 h, 24 h, and 36 h when the parasites were in the ring, trophozoite, and schizont
stages, respectively (3). Total RNA was isolated as described above from each
parasite stage. An equal amount of RNA (1 g) from each stage was used as a
template to amplify PfCK, keeping other conditions the same as mentioned
above for RT-PCR amplification. Simultaneously, positive-control primers for
seryl tRNA synthetase were added in each RT-PCR. Seryl tRNA synthetase is
expressed equally in each stage of P. falciparum (9). Primer sequences used for
seryl tRNA synthetase were 5-GAGGAATTTTACGTGTTCATCAA-3 (for-
ward) and 5-GATTACTTGTAGGAAAGAATCCTTC-3 (reverse). RT-PCR
products were analyzed through electrophoresis on 1% agarose gel in Tris-
acetate-EDTA buffer at 10 V/cm. The gel was photographed with a Gel
Documentation system (Alpha Infotech, India). The intensity of bands was
measured with densitometric software (Lab Image beta version; Kapelan
GmbH, Germany).
To investigate the pattern of expression of PfCK in different stages of P.
falciparum at the protein level, immunofluorescence microscopy was performed.
In brief, asynchronous P. falciparum culture (50 l in CRPMI medium at 4 to 5%
parasitemia) was incubated with 250 nM MitoTracker Red CMXRos for 30 min
under optimum growth conditions in the dark. Three successive washings with
CRPMI medium removed unincorporated MitoTracker Red CMXRos. In order
to obtain a concentrated suspension, the cells were finally resuspended in 10 l
of CRPMI medium and smeared on poly-L-lysine-coated glass coverslips. Smears
were allowed to air dry and fixed in methanol:acetone (7:3 [vol/vol]) for 20 min
at 20°C. Subsequently, cells were washed and hydrated in PBS and then
permeabilized in 0.1% Triton X-100 for 20 min at 30°C. Permeabilized cells on
the coverslips were washed four or five times with PBS for complete removal of
Triton X-100. Blocking was performed with 5% (wt/vol) bovine serum albumin
(BSA) in PBS for 20 min at 30°C, followed by four or five washes in PBS.
Subsequently, smears were incubated for 16 h at 4°C with anti-PfCK antibodies
(at a dilution of 1:50 in 2% [wt/vol] BSA in PBS) and washed with ice-cold PBS
four or five times. Smears were further incubated with anti-rabbit IgG coupled to
Cy2 at a dilution of 3.6 g/ml (protein) in 2% BSA in PBS for 5 to 6 h at 4°C and
then were washed with PBS four or five times. Subsequently, nuclear DNA of the
parasite was stained with 20 g/ml DAPI in PBS for 45 min at 30°C with gentle
agitation and then washed with PBS four or five times. Finally, coverslips were
mounted on slides in mounting medium containing paraphenyl diamine (Sigma)
dissolved in 90% glycerol. Fluorophores were excited with excitation wavelengths
of 350 nm (for DAPI), 579 nm (for MitoTracker Red CMXRos), and 489 nm (for
Cy2-tagged anti-rabbit IgG), and their emissions at 470-nm (for DAPI), 599-nm
(for MitoTracker Red CMXRos), and 506-nm (for Cy2-tagged anti-rabbit IgG)
wavelengths were observed with a fluorescence microscope.
Effects of HDTAB on phosphocholine and phosphatidylcholine formation in
P. falciparum. To study the effect of HDTAB on the Kennedy pathway of malaria
parasite, an experiment was performed to investigate the incorporation of ra-
diolabeled choline into different metabolites of the pathway by the method
described earlier (36). P. falciparum culture (5 ml) at 15% parasitemia and 5%
hematocrit level was incubated with DMSO (control) or various concentrations
of HDTAB for 1 hour under the optimum growth conditions (at 37°C under 90%
N2 and 5% CO2). Subsequently, 40 M [methyl-14C]choline chloride (specific
activity, 5.6 mCi/mmol) was added to the culture and further grown under the
identical conditions for 4 h. On completion of incubation, cells were pelleted at
800  g, the culture medium was discarded, and the cells were washed three
times with ice-cold PBS containing 40 M nonradiolabeled choline chloride.
Choline, phosphocholine, and phosphatidylcholine were extracted from the cells
by a combination of the methods described earlier (18, 35). Cells were lysed in
5% trichloroacetic acid and then subjected to three cycles of freeze-thawing for
complete lysis of the cells (35). Cell lysates were centrifuged at 12,000  g and
4°C for 30 min to precipitate proteins and membranes (containing phosphati-
dylcholine) in the pellet. Pellets were dissolved in 500 l of 1 N NaOH and added
to 10 ml scintillation fluid. Supernatant containing phosphocholine and choline
was extracted five times with diethyl ether to remove trichloroacetic acid, and
then the pH of the aqueous phase was adjusted with 0.1 N NaOH to pH 7. For
separation of choline and phosphocholine, the aqueous phase was vigorously
mixed with 300 mg of Dowex-50W [H] resin which binds only choline (18).
Resin was allowed to settle, and supernatant containing phosphocholine was
mixed in 10 ml of scintillation fluid. Choline from the Dowex-50W [H] resin
was recovered by vigorously mixing the resin in 500 l of 1 N HCl for 5 min.
Resin was allowed to settle under gravity, and supernatant was added to 10 ml
of scintillation fluid. Counts were taken in a liquid scintillation -counter
(Beckman).
Toxicity assay. Hemolytic activity of HDTAB was evaluated by the method
described earlier (7) with slight modifications. Human B RBCs were incubated
in 96-well plates either in the presence of DMSO (control) or in the presence of
various concentrations of HDTAB for 24 h in 200 l complete RPMI medium at
5% hematocrit level. RBCs were washed thrice in CRPMI following HDTAB
removal and inoculated with 20 l of P. falciparum parasitized RBCs (human
B) growing at 5% hematocrit level and 4 to 5% parasitemia (mostly tropho-
zoites). Parasites were allowed to complete one intraerythrocytic cycle, 0.7 Ci
[3H]hypoxanthine was added to each well, and the culture was further incubated
for 24 h under optimum conditions. On completion of incubation, cells were
harvested on Whatman GF/C glass filters with a cell harvester, and samples were
processed as described above.
Cytotoxicity of HDTAB was also evaluated against growing nucleated mam-
malian cells (MCF-7) using a colorimetric assay for lactate dehydrogenase
(LDH) release. Exponentially growing MCF-7 cells were seeded in 96-well tissue
culture plates at a density of 2  104 cells per well in triplicate and cultured for
24 h in Dulbecco modified Eagle medium supplemented with 10% fetal calf
serum at 37°C in 5% humidified CO2. Following incubation, culture medium was
replaced with 200 l of fresh medium containing either different concentrations
of HDTAB (dissolved in DMSO) or DMSO (as a negative control). As a positive
control, cells were treated with 0.9% Triton X-100. The culture plate was then
incubated for 7 h, and 50 l of the supernatant from each well of the assay plate
was taken from the corresponding well of a flat-bottom 96-well plate. Color
reaction for LDH assay was performed using the CytoTox kit (Promega) by
following the instructions of the manufacturer. Optical densities at 490 nm were
measured in a microplate reader. Comparative analysis of LDH release was
performed by setting LDH release in Triton X-100-treated cells at 100%.
In vivo antimalarial activity. The in vivo efficacy of HDTAB was evaluated
against P. yoelii (N-67 strain) in Swiss mice at three dose levels. In the first
experiment, a group of five mice (22  2 g) were inoculated intraperitoneally
(i.p.) with 1  105 parasitized RBCs on day 0 and HDTAB was administered
after 6 h of parasite inoculation via the i.p. route. In another experiment, a group
of five mice (22  2 g) were inoculated intravenously (i.v.) with 1  104 para-
sitized RBC on day 0, and HDTAB was administered after 6 h of parasite
inoculation via the i.p. route. In both experiments, the treatment was continued
at each dose level from day 0 to 3 via the intraperitoneal route. The aqueous
suspension was prepared so as to obtain the required drug dose per animal in
0.20ml volume. Parasitemia levels from individual mice were recorded in
Giemsa-stained thin blood smears on day 4. The mean value determined for a
group of five mice was used to calculate the percentage of suppression in para-
sitemia with respect to the vehicle control group.
Statistical analysis. The data were analyzed by Student’s t test and one-way
analysis of variance, followed by multiple-comparison t test.
RESULTS
HDTAB inhibits purified PfCK. H-89 and HC-3 are known
to inhibit choline kinase in various cells (8, 44). The effects of
these inhibitors and choline analogue HDTAB on PfCK were
investigated with the view of identifying a selective and potent
inhibitor to explore the function of CK in P. falciparum growth
and survival during intraerythrocytic stages. H-89, the known
protein kinase A inhibitor (14), has also been reported to
inhibit choline kinase of HeLa cells (44) but failed to inhibit
purified PfCK (Fig. 2A and B). PfCK activity was measured at
two different concentrations of ATP (5 mM and 100 M) in
the presence of H-89, and DMSO-treated PfCK was used as a
control (as H-89 was dissolved in DMSO). H-89 had no effect
on PfCK at an ATP concentration of 5 mM, since PfCK treated
with H-89 catalyzed the formation of phosphocholine as effi-
ciently as control cells (DMSO-treated PfCK) did (Fig. 2A).
Since inhibition of protein kinase A by H-89 was found to be
competitive in nature with respect to ATP (25), the concen-
tration of ATP was decreased to 100 M to assay PfCK in the
presence or absence of H-89. Decreasing the ATP concentra-
tion to 100 M had no effect on PfCK, as H-89-treated PfCK
displayed activity comparable to control PfCK activity (Fig.
2B). A possible explanation of this inability of H-89 to inhibit
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purified PfCK is that H-89 offered its choline kinase inhibitory
effect in intact HeLa cells where it could affect choline kinase
activity via inhibition of protein kinase A and C, as growing
evidence has established that phosphorylation of choline ki-
nase by protein kinase A and C increases its activity (15, 45).
The known choline transport inhibitor HC-3 (22, 37) has been
reported to have a choline kinase-inhibitory effect (8). There-
fore, the effect of HC-3 on PfCK was evaluated. Since HC-3
contains a quaternary ammonium group that mimics choline
structure, PfCK activity was studied at two concentrations of
choline, namely, 250 M and 100 M. At both choline con-
centrations, PfCK was not significantly inhibited by HC-3 up to
25 M (Fig. 2C and D). However, poor inhibition of only 16%
and 18% was observed at 50 M and 150 M, respectively, at
both 100 and 250 M choline. A similar level of inhibition by
HC-3 has also been reported earlier in the malaria parasite
lysate for choline kinase activity (6). These results indicated
that HC-3 is not a strong inhibitor of PfCK. Development of
specific choline kinase inhibitors based on the structure of
HC-3 (23, 24) and a mild inhibition of PfCK by HC-3 induced
interest in studying the effects of other quaternary ammonium
compounds on PfCK activity. The quaternary ammonium com-
pound selected for the study was HDTAB because it has a
quaternary ammonium group as well as its structure is very similar
to the structure of hexadecylphosphocholine (miltefosin), a mol-
ecule widely used as an antiproliferative (10) and antileishmanial
drug (11, 30). HDTAB inhibited PfCK in a dose-dependent
manner and showed 60% (P 	 0.001) inhibition at 100 M
FIG. 2. Effects of H-89, HC-3, and HDTAB on PfCK activity. PfCK activity was evaluated in the presence or absence of the indicated
concentrations of H-89, HC-3, and HDTAB. The effect of H-89 on PfCK was evaluated at 5 mM (A) and 100 M (B) ATP. The effect of HC-3
on PfCK was studied at 250 M (C) and 100 M (D) choline concentrations. Similarly, the effect of HDTAB on PfCK was also studied at 250
M (E) and 100 M (F) choline concentrations as described in Materials and Methods. PfCK activity was expressed as the amount of
phosphocholine generated (counts per minute). Data are presented as means  standard errors of the means (error bars) for three different
experiments performed in triplicate.
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(Fig. 2E). To investigate the type of inhibition exerted by
HDTAB, choline concentration was decreased from 250 M to
100 M in the assay system. Comparison of the percentages of
inhibition offered by different concentrations of HDTAB at
both choline concentrations suggested that a decrease in the
choline concentration shifted the concentration required for
60% inhibition of PfCK from 100 M to 50 M (Fig. 2F). The
observed shift indicated that HDTAB may compete with cho-
line for the choline binding site of PfCK and may offer com-
petitive inhibition with respect to choline.
Antimalarial effect of HDTAB. We showed above that
HDTAB had an inhibitory effect on PfCK. Therefore, to eval-
uate the importance of choline kinase in P. falciparum growth
and survival, P. falciparum was cultured in the presence or
absence of HDTAB. Interestingly, HDTAB inhibited the
growth of malaria parasite in a dose-dependent manner with
62% (P 	 0.001) and 81% (P 	 0.001) growth inhibition at 10
M and 20 M, respectively (Fig. 3).
Sensitivity of different erythrocytic stages of Plasmodium
falciparum to HDTAB. It is evident from the existing literature
that antimalarial compounds have stage specificity in their
antimalarial effect. For instance, artemisinin exerts its antima-
larial effect by killing malaria parasites at early stages of in-
traerythrocytic growth (34), whereas quinoline derivatives like
chloroquine kill malaria parasites in its mature stage (33).
Therefore, the sensitivity of different erythrocytic stages of P.
falciparum toward HDTAB was evaluated. HDTAB at a con-
centration of 10 M inhibited 62% (P 	 0.001) and 51% (P 	
0.001) growth of P. falciparum at trophozoite and schizont
stages, respectively (Fig. 4B and C). Whereas even at three-
fold-higher concentration (30 M), it inhibited only 33.3% of
growth of parasites at the ring stage (Fig. 4A). Comparison of
growth inhibition among these stages clearly suggested that
HDTAB had the highest inhibitory activity toward trophozo-
ites (Fig. 4D). Thus, results clearly indicated the stage speci-
ficity of antimalarial action of HDTAB. The results also raised
the question of why this sensitivity is to trophozoites and schiz-
onts only and not to rings. Is there any stage specificity in the
expression pattern of PfCK? Is PfCK expressed strongly at the
trophozoite and schizont stages? To test the hypothesis that
HDTAB inhibits PfCK and thus offers an antimalarial effect,
RT-PCR and immunofluorescence microscopic analysis were
performed to investigate any possible stage specificity in the
expression pattern of PfCK.
Evidence for stage-specific expression of PfCK. P. falcipa-
rum expresses proteins differentially depending on the need for
a particular stage. To check whether PfCK is expressed at a
specific stage, RT-PCR was performed using total RNA (as a
template) extracted separately from the ring, trophozoite, and
schizont stages of P. falciparum and using a set of primers
specific for PfCK (Fig. 5A). Amplification of a fragment of 1.3
kb, the predicted size of PfCK, was found by RT-PCR with the
RNA from trophozoites (Fig. 5A, lane T) and schizonts (Fig.
5A, lane S) but not from the ring stage (Fig. 5A, lane R),
indicating stage-specific expression of the PfCK gene. In con-
trast, the expression pattern of the seryl tRNA synthetase
(control) was not affected by the different stages of the malaria
parasite (Fig. 5A, lanes R, T, and S). Densitometric analysis
suggested that the highest expression of PfCK takes place at
the trophozoite stage of the malaria parasite (Fig. 5B). To
further confirm the stage specificity of PfCK expression in P.
falciparum at the protein level, immunofluorescence micro-
scopic analysis was performed using anti-PfCK antibodies (Fig.
5C). Immunofluorescence microscopic results clearly sug-
gested that PfCK expression predominates in the mature
stages of the malaria parasite, i.e., trophozoites and schizonts
(Fig. 5C, T and S panels), whereas expression of PfCK was
completely absent in the ring stage of malaria parasites (Fig.
5C, R panels). These results corroborated the RT-PCR results
and confirmed that higher expression of PfCK in P. falciparum
takes place in the mature stages of the parasite, which are the
most sensitive stages for HDTAB as described above. These
results including in vitro PfCK inhibition by HDTAB together
indicated that HDTAB might utilize PfCK as its target to exert
antimalarial activity. Examining the effect of HDTAB on the
CDP-choline pathway in the biosynthesis of PC would certainly
provide further details on the mode of action of HDTAB.
HDTAB inhibits choline kinase of Plasmodium falciparum in
culture. So far, results have indicated that purified PfCK is
inhibited by HDTAB, which has antimalarial activity. The an-
timalarial activity of HDTAB is specific for the trophozoite
and schizont stages, where the highest PfCK expression occurs,
suggesting that HDTAB may exhibit antimalarial activity
through PfCK inhibition. Direct measurement of phosphocho-
line (as a measure of PfCK activity) in HDTAB-treated and
nontreated P. falciparum cells would be useful in determining
the mode of action of HDTAB. The effect of HDTAB on
phosphatidylcholine biosynthesis in P. falciparum was studied.
For this, P. falciparum was cultured in CRPMI containing
[methyl-14C]choline chloride after HDTAB or DMSO (con-
trol) treatment, and the incorporation of radiolabeled choline
into different metabolites of the Kennedy pathway was moni-
tored. HDTAB significantly inhibited the incorporation of
[methyl-14C]choline into phosphocholine in a dose-dependent
FIG. 3. Antimalarial effect of HDTAB. Asynchronous P. falcipa-
rum culture (200 l, 0.5 to 0.7% parasitemia) was incubated either with
the indicated concentrations of HDTAB or with DMSO (control) for
one complete cycle (48 h). Incorporation of [3H]hypoxanthine in P.
falciparum was determined as described in Materials and Methods.
Incorporation of [3H]hypoxanthine is presented in counts per minute.
(Inset) Percent growth inhibition offered by HDTAB calculated from
the incorporation of [3H]hypoxanthine in HDTAB-treated cells com-
pared to the DMSO control, which was taken as 100% growth or 0%
growth inhibition. Data are presented as means  standard errors of
the means (error bars) for three different experiments performed in
triplicate.
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manner with a 57% (P 	 0.001) decrease at 10 M (Fig. 6A).
This reduction in phosphocholine could be a result of either
choline kinase inhibition or inhibition of choline transport,
which in turn resulted in decreased phosphocholine genera-
tion. Therefore, to determine intracellular free choline, control
parasites and HDTAB-treated parasites were compared. Par-
asites treated with 10 M HDTAB showed 42% (P 	 0.001)
less intracellular free choline than control parasites did (Fig.
6B). The reduction in intracellular free choline and phospho-
choline generation clearly suggested that not only choline ki-
nase activity of malaria parasite but also choline transport was
inhibited by the HDTAB. These results supported the earlier
reported role of choline kinase in trapping choline inside the P.
falciparum cells by its phosphorylation (29). In addition, the
decrease in phosphocholine generation resulted in a decrease
in phosphatidylcholine biosynthesis (Fig. 6C). HDTAB treat-
ment caused a dose-dependent decrease in phosphatidylcho-
line biosynthesis (Fig. 6C), which correlated well with the de-
crease in phosphocholine generation, indicating that choline
kinase may regulate PC biosynthesis in P. falciparum (Fig. 6D).
Parallel decreases in phosphocholine and phosphatidylcholine
were found and also correlated well with the decrease in the
parasitic growth (Fig. 6D), indicating that the perturbation of
PC biosynthesis led to the death of the parasite. A similar
correlation in phosphocholine generation and PC biosynthesis
after treatment with other quaternary ammonium compounds
was earlier reported (4). These results clearly indicated that
HDTAB offered antimalarial activity via inhibition of choline
kinase and also advocated the critical role of choline kinase in
P. falciparum growth and stage progression.
HDTAB has no toxic effect on the viability of RBC. HDTAB
has a very long aliphatic chain, which causes its detergent-like
properties. Thus, to investigate whether HDTAB has any spec-
ificity for the malaria parasite or whether it lyses any type of
biological membrane including RBC membrane, normal unin-
fected RBCs were incubated with HDTAB at different con-
centrations. Following incubation, RBCs were infected with P.
falciparum-infected erythrocytes and [H3]hypoxanthine uptake
was monitored. Incorporation of [H3]hypoxanthine in P. fal-
ciparum cultured in RBCs treated with 5, 10, 15, 20, 25, and 30
FIG. 4. Stage-specific antimalarial effect of HDTAB. P. falciparum culture was synchronized using 5% D-sorbitol, and parasitemia was
adjusted to 0.5 to 0.7% at a hematocrit level of 1% with fresh and uninfected B human RBCs. Incorporated [3H]hypoxanthine was
determined as described in Materials and Methods. [3H]hypoxanthine incorporation in ring (A), trophozoite (B), and schizont (C) stages of
P. falciparum is presented as counts per minute. (D) Growth inhibitory effect of HDTAB toward rings, trophozoites, and schizonts.
Incorporation of [3H]hypoxanthine in HDTAB-treated cells was measured and compared to the value in the DMSO control, which was taken
as 100% growth or 0% growth inhibition. Data are presented as means  standard errors of the means (error bars) for three different
experiments performed in triplicate.
VOL. 51, 2007 INHIBITION OF PfCK BY HDTAB 701
 o
n
 August 14, 2014 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
FIG. 5. Stage-specific expression of PfCK. (A) Agarose gel of RT-PCR products. Total RNA from a synchronized P. falciparum culture was
isolated at 0 h, 24 h, and 36 h when the parasites were in the ring, trophozoite, and schizont stages, respectively. Total RNA (1 g) was subjected
to RT-PCR using specific primers for PfCK and seryl tRNA synthetase (control) as described in Materials and Methods. Lane M, DNA ladder;
lane R, ring stage; lane T, trophozoite stage; lane S, schizont stage. (B) Densitometry of PfCK expression. Densitometric analysis of PfCK
expression in different stages of Plasmodium falciparum. The intensity of PfCK was normalized to that of seryl tRNA synthetase. (C) Immuno-
fluorescence microscopy. Slides were prepared as described in Materials and Methods. Different fields were observed with excitation wavelengths
of 350 nm (DAPI), 579 nm (MitoTracker Red CMXRos), and 489 nm (Cy2). Blue, red, and green fluorescence indicate the locations of nucleus
(a), mitochondria (b), and PfCK (c) in Plasmodium falciparum, respectively. (d) Merged picture of panel a, b, and c pictures. Mononuclear (R
panels), binuclear (T panels), and multinuclear (S panels) P. falciparum cells represent rings, trophozoites, and schizonts, respectively.
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M HDTAB was comparable to that in the control as evident
from Fig. 7A. These results suggest that HDTAB up to 30 M
did not affect the ability of RBCs to support parasite invasion
and growth. Therefore, it can be concluded that HDTAB does
not affect the viability of the RBCs and that its antimalarial
action is specific to the parasite only. To study the toxicity of
HDTAB on nucleated mammalian cells, MCF-7 cells were
incubated with 5 to 30 M HDTAB and then the LDH release
assay was conducted. It was found that HDTAB had no sig-
nificant toxicity for mammalian nucleated cells (Fig. 7B).
In vivo antimalarial activity against rodent malaria parasite
P. yoelii. The in vitro antimalarial activity of HDTAB encour-
aged us to evaluate the effect of HDTAB against the rodent
malarial parasite Plasmodium yoelii (N-67 strain) in vivo. Two
approaches were used. In the first approach, HDTAB treat-
ment was administered 6 h after the inoculation of infection
from the same route, i.e., intraperitoneally. Following this reg-
imen, HDTAB suppressed the day 4 mean parasitemia by
36.77, 52.44, and 77.17% at dose levels of 5 mg/kg of body
weight, 10 mg/kg, and 20 mg/kg, respectively (Table 1). These
results suggested that HDTAB also has a potent antimalarial
activity in vivo, but this antimalarial activity could have re-
sulted from a local effect of HDTAB, since infection or treat-
ment was given by the same route, which might not have
allowed parasites to circulate and grow in the animal body. To
rule out this possibility, another approach in which parasites
were inoculated via the i.v. route and treatment was adminis-
tered intraperitoneally was used. The antimalarial activity of
HDTAB was also unaffected by this regimen, and mean para-
sitemia suppression values of 48.70, 64.25, and 83.68% were
observed at day 4 at dose levels of 5 mg/kg, 10 mg/kg, and 20
mg/kg, respectively (Table 1). The results suggest that the
time lag between parasite inoculation and administration of
HDTAB and the different routes for inoculation and treat-
ment did not influence the antimalarial activity of HDTAB,
indicating a systemic mode of antimalarial effect of HDTAB.
DISCUSSION
The ability of quaternary ammonium compounds to inter-
fere with different enzymatic steps of the CDP-choline pathway
led us to study the effect of HDTAB on PfCK activity. A
smaller derivative of the same compound, decyltrimethylam-
monium bromide shown in Fig. 1, has already been reported to
have antimalarial activity without having any adverse effect on
RBCs (7). Miltefosin inhibits the CDP-choline pathway (26)
(Fig. 1) and offers antiproliferative, antileishmanial, and anti-
malarial drug activity (10, 11, 30, 32). The mode of action in
the latter two cases has not been well defined. For antiprolif-
erative activity, miltefosin acts by inhibiting choline phosphate
FIG. 6. Effect of HDTAB on the CDP-choline pathway. P. falciparum culture (5 ml) at 15% parasitemia and 5% hematocrit was exposed to
the indicated concentrations of HDTAB or DMSO (control) for 1 hour. Subsequently, HDTAB was removed and cells were washed thrice with
CRPMI medium, and then 40 M [methyl-14C]choline chloride (specific activity, 5.6 mCi/mmol) was added. Cells were further grown for 4 h under
optimum growth conditions. Following incubation, choline, phosphocholine, and phosphatidylcholine were extracted as described in Materials and
Methods. (A) Incorporation of [methyl-14C]choline in phosphocholine; (B) intracellular free [methyl-14C]choline in P. falciparum cells; (C) incor-
poration of [methyl-14C]choline in phosphatidylcholine; (D) percent [methyl-14C]choline incorporation in phosphocholine and phosphatidylcholine
and its correlation with percent growth of P. falciparum at different concentrations of HDTAB. Data are presented as means  standard errors
of the means (error bars) of three different experiments performed in triplicate.
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cytidylyltransferase (CCT), the regulatory enzyme of the CDP-
choline pathway, since miltefosin mimics the structure of phos-
phocholine, the substrate for CCT (Fig. 1).
The importance of choline kinase in P. falciparum was eval-
uated by incubating the P. falciparum culture in the presence of
HDTAB. HDTAB inhibited the growth of P. falciparum very
efficiently. The concentration of HDTAB required to inhibit P.
falciparum growth by 62% was 10 times lower than the con-
centration required to inhibit purified PfCK by 60% in vitro.
The apparent difference in action could be attributed to the
choline transporter in the malaria parasite membrane, which
has been found to accumulate quaternary ammonium com-
pounds inside the malarial parasite to the millimolar range
from the nanomolar external concentration (12, 13, 38, 43).
There are several other mono and bis quaternary ammonium
compounds with long aliphatic chains that have been found to
inhibit P. falciparum growth in vitro (1, 3, 4, 7) and in vivo (2,
43). This class of antimalarials is not only active against chlo-
roquine-sensitive strains of P. falciparum but is also equally
effective against multiple drug-resistant strains of P. falciparum
(1, 3). Similarly, HDTAB has also exhibited potent antimalar-
ial activity in vivo against the chloroquine-resistant rodent ma-
larial parasite Plasmodium yoelii (N-67 strain). The exact mode
of action of these quaternary ammonium compounds is not
fully understood, but ample evidence suggested that these
compounds target enzymatic steps of the Kennedy pathway,
including choline kinase (3, 36).
The results of our stage-specific RT-PCR and immunofluo-
rescence microscopic analysis suggested that PfCK is expressed
during the mature intraerythrocytic stages (trophozoites and
schizonts) of the parasite, which coincides perfectly with the
timing of higher phosphatidylcholine biosynthesis in the para-
site (5). These results were also in agreement with the DNA
microarray data available at www.PlasmoDB.org for the ex-
pression profile of the PfCK gene. The stage-specific expres-
sion of PfCK and antiplasmodial activity of HDTAB raised
interest in investigating whether HDTAB has any stage spec-
ificity in its action. Interestingly, we found that the mature
stages, i.e., trophozoites and schizonts, of the intraerythrocytic
cycle of P. falciparum were much more susceptible to HDTAB
than malaria parasites in the ring stage were. At these stages,
malaria parasites multiply, and inhibition of choline kinase
results in the inhibition of phosphocholine production, which
in turn affects the biosynthesis of phosphatidylcholine, the ma-
jor component of the malaria parasite membrane. Moreover,
phosphocholine has also been recognized as an important sec-
ondary signal molecule in the process of mitogenesis (19, 21,
28). Reduced phosphocholine generation via inhibition of cho-
line kinase may also have an adverse effect on the ongoing
mitogenic process during the mature stages of malaria para-
sites, thereby explaining the higher susceptibility of the mature
FIG. 7. Toxicity of HDTAB toward RBCs and MCF-7 cells. (A) Fresh and uninfected human B RBCs were incubated with the indicated
concentrations of HDTAB for 24 h. After completion of incubation, cells were washed thrice with CRPMI medium and infected with P. falciparum
culture. [3H]hypoxanthine uptake was studied as described in Materials and Methods. Incorporation of [3H]hypoxanthine is presented in counts
per minute. (Inset) Percent growth inhibition offered by HDTAB calculated from incorporation of [3H]hypoxanthine in HDTAB-treated cells
compared to the DMSO control, which was taken as 100% growth or 0% growth inhibition. (B) Exponentially growing MCF-7 cells were seeded
in 96-well plates at a concentration of 2  104 cells per well and cultured for 24 h in Dulbecco modified Eagle medium. Subsequently, culture
medium was changed, and in fresh medium, cells were incubated with the indicated concentrations of HDTAB, DMSO (negative control), and
0.9% Triton X-100 (Tx) (positive control) for 7 h. Then, LDH release was estimated as described in Materials and Methods. Data are presented
as means  standard errors of the means (error bars) for three different experiments performed in triplicate.
TABLE 1. In vivo antimalarial activity of HDTAB against the
chloroquine-resistant rodent malaria parasite
Plasmodium yoelii (strain N-67)
HDTAB dose
(mg/kg)a
Mean % parasitemia suppression
on day 4b
i.v. i.p.
5 48.70 36.77
10 64.25 52.44
20 83.68 77.17
0 (vehicle) (control) 0 0
a HDTAB treatment was given by the intraperitoneal route in each case.
b Parasites were inoculated intravenously or intraperitoneally. Percent sup-
pression was calculated as 
(C  T)/C  100, where C is parasitemia in the
control group and T is parasitemia in the treated group.
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stages of the malaria parasite to HDTAB compared to that of
malaria parasites in the ring stage.
To investigate whether HDTAB actually inhibits the choline
kinase of P. falciparum inside the cell, radiolabeled choline incor-
poration into different metabolites of the CDP-choline pathway
was monitored. The incorporation of radiolabeled choline into
phosphocholine was reduced by 57% in the 10 M HDTAB-
treated P. falciparum culture compared to the control culture,
and a concomitant reduction in the incorporation of radiola-
beled choline into phosphatidylcholine was also observed. This
indicates that choline kinase may have a regulatory role in
phosphatidylcholine biosynthesis, as its inhibition by HDTAB
reduced the production of phosphocholine, which in turn de-
creased phosphatidylcholine biosynthesis. These results are
consistent with the earlier report where a good correlation
between the intracellular phosphocholine pool and phosphati-
dylcholine content had been found by treatment with certain
quaternary ammonium compounds (4). Choline kinase has
been reported to assist choline transport by its phosphorylation
in P. falciparum (29). Therefore, intracellular free choline lev-
els in control parasites and HDTAB-treated parasites were
compared. Parasites treated with HDTAB at a concentration
of 10 M had 42% less intracellular free choline than control
parasites did, reconfirming the previously reported role of cho-
line kinase in choline transport by phosphorylation (29).
HDTAB is well-known for its detergent properties and
may act by solubilizing biological membranes nonspecifically.
Therefore, to investigate whether HDTAB has any specificity
for the malaria parasite or whether it lyses any type of biolog-
ical membrane, including the RBC membrane, normal unin-
fected RBCs were incubated with HDTAB. Subsequently,
treated RBCs were infected with P. falciparum, and [3H]hy-
poxanthine uptake was monitored. Incorporation of [3H]hy-
poxanthine into P. falciparum cultured in HDTAB-treated
RBCs was comparable with that of the control, indicating that
incubation of RBCs with HDTAB did not affect the ability of
RBCs to support parasite invasion and growth up to 30 M
concentration. Therefore, HDTAB does not affect the viability
of RBCs or the integrity of the RBC membrane. HDTAB did
not show any cytolytic effect on proliferating nucleated mam-
malian cells (MCF-7) as measured by LDH release up to 30
M. Thus, the exhibited antimalarial action of HDTAB is
specific to the parasite only.
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